LIQUIDIA CORPORATION Revenue
LIQUIDIA CORPORATION (LQDA) reported Revenue of $171.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- LIQUIDIA CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $171.68M, a 1842.73% increase year-over-year.
- LIQUIDIA CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $132.87M, a 4158.49% increase year-over-year.
- LIQUIDIA CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $92.02M, a 3054.65% increase year-over-year.
- LIQUIDIA CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $54.34M, a 1121.72% increase year-over-year.
- LIQUIDIA CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $158.32M, a 1031.18% increase from fiscal 2024.
- LIQUIDIA CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2024 was $14.00M, a 19.97% decline from fiscal 2023.
- LIQUIDIA CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2023 was $17.49M, a 9.75% increase from fiscal 2022.
- LIQUIDIA CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $15.94M, a 23.98% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $171.68M 10-Q · filed 2026-08-12 | $304.54M 10-Q · filed 2026-08-12 | $396.56M derived: sum of 3 quarters · filed 2026-08-12 | $450.91M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $132.87M 10-Q · filed 2026-05-11 | $224.89M derived: sum of 2 quarters · filed 2026-05-11 | $279.23M derived: sum of 3 quarters · filed 2026-05-11 | $288.06M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $92.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $146.36M derived: sum of 2 quarters · filed 2026-03-05 | $155.20M derived: sum of 3 quarters · filed 2026-08-12 | $158.32M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $54.34M 10-Q · filed 2025-11-03 | $63.18M derived: sum of 2 quarters · filed 2026-08-12 | $66.30M 10-Q · filed 2025-11-03 | $69.22M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $8.84M 10-Q · filed 2026-08-12 | $11.96M 10-Q · filed 2026-08-12 | $14.87M derived: sum of 3 quarters · filed 2026-08-12 | $19.32M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $3.12M 10-Q · filed 2026-05-11 | $6.04M derived: sum of 2 quarters · filed 2026-05-11 | $10.48M derived: sum of 3 quarters · filed 2026-05-11 | $14.14M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $2.92M 8-K · filed 2025-05-08 | $7.37M derived: sum of 2 quarters · filed 2025-11-03 | $11.02M derived: sum of 3 quarters · filed 2025-11-03 | $14.00M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $4.45M 10-Q · filed 2025-11-03 | $8.11M derived: sum of 2 quarters · filed 2025-11-03 | $11.08M 10-Q · filed 2025-11-03 | $15.61M derived: sum of 4 quarters · filed 2025-11-03 | ||||
| 2024-06-30 | $3.66M 10-Q · filed 2025-08-12 | $6.63M 10-Q · filed 2025-08-12 | $11.16M derived: sum of 3 quarters · filed 2025-08-12 | $14.84M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $2.97M 8-K · filed 2025-05-08 | $7.50M derived: sum of 2 quarters · filed 2025-05-08 | $11.18M derived: sum of 3 quarters · filed 2025-05-08 | $15.97M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $4.53M 8-K · filed 2025-05-08 | $8.21M derived: sum of 2 quarters · filed 2025-05-08 | $12.99M derived: sum of 3 quarters · filed 2025-05-08 | $17.49M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $3.68M 8-K · filed 2025-05-08 | $8.46M derived: sum of 2 quarters · filed 2025-05-08 | $12.96M 10-Q · filed 2024-11-13 | $18.32M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-06-30 | $4.79M 8-K · filed 2025-05-08 | $9.28M 10-Q · filed 2024-08-07 | $14.64M derived: sum of 3 quarters · filed 2025-05-08 | $17.80M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-03-31 | $4.49M 8-K · filed 2025-05-08 | $9.85M derived: sum of 2 quarters · filed 2025-05-08 | $13.02M derived: sum of 3 quarters · filed 2025-05-08 | $16.94M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2022-12-31 | $5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $8.53M derived: sum of 2 quarters · filed 2024-03-13 | $12.44M derived: sum of 3 quarters · filed 2024-03-13 | $15.94M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $3.17M 10-Q · filed 2023-11-07 | $7.08M derived: sum of 2 quarters · filed 2023-11-07 | $10.57M 10-Q · filed 2023-11-07 | $13.79M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $3.92M 10-Q · filed 2023-08-10 | $7.41M 10-Q · filed 2023-08-10 | $10.63M derived: sum of 3 quarters · filed 2023-08-10 | $13.80M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $3.49M 10-Q · filed 2023-05-08 | $6.71M derived: sum of 2 quarters · filed 2023-05-08 | $9.89M derived: sum of 3 quarters · filed 2023-05-08 | $13.26M derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $6.39M derived: sum of 2 quarters · filed 2023-03-20 | $9.77M derived: sum of 3 quarters · filed 2023-03-20 | $12.85M 10-K · filed 2023-03-20 | $12.85M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $3.18M 10-Q · filed 2022-11-08 | $3.18M 10-Q · filed 2021-11-03 | $6.55M derived: sum of 2 quarters · filed 2022-11-08 | $9.64M 10-Q · filed 2022-11-08 | $9.64M 10-Q · filed 2021-11-03 | $10.38M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $3.38M 10-Q · filed 2022-08-11 | $3.38M 10-Q · filed 2021-08-10 | $6.46M 10-Q · filed 2022-08-11 | $6.46M 10-Q · filed 2021-08-10 | $7.20M derived: sum of 3 quarters · filed 2022-08-11 | $7.20M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $3.08M 10-Q · filed 2022-05-12 | $3.08M 10-Q · filed 2021-05-13 | $3.82M derived: sum of 2 quarters · filed 2022-05-12 | $3.82M derived: sum of 3 quarters · filed 2022-05-12 | $3.82M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $739.63K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $739.63K derived: sum of 2 quarters · filed 2022-03-17 | $739.63K derived: sum of 3 quarters · filed 2022-03-17 | $739.63K 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | $8.07M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |